Screener
Ginkgo Bioworks DNA Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $172.02M-31.6% | $188.67M-46.9% | $212.37M-64.9% | $156.96M-76.3% | $251.35M-67.6% | ||
| $13.01M-41.3% | $19.82M-24.6% | $24.03M+9.9% | $21.43M-8.5% | $22.15M+19.2% | ||
| $332.54M-36.4% | $409.96M-27.4% | $471.84M-21.7% | $506.08M-23.6% | $523.03M-33.2% | ||
| $157.19M-15.7% | $163.02M-17.6% | $167.37M-17.8% | $176.58M-16.3% | $186.35M-11.5% | ||
| $44.39M-32.9% | $48.86M-28.9% | $56.92M-21.5% | $61.52M-22.7% | $66.15M-27.0% | ||
| $14.78M-54.8% | $14.7M-54.3% | $15.07M-69.1% | $30.18M-51.4% | $32.66M-47.7% | ||
| $990.05M-19.6% | $1.03B-20.1% | $1.12B-18.7% | $1.19B-19.7% | $1.23B-24.3% | ||
| $13.21M-53.3% | $14.91M-55.7% | $18.95M-31.6% | $25.24M+10.2% | $28.29M+8.8% | ||
| $72.74M-24.8% | $79.6M-31.2% | $95.97M-10.5% | $115.28M+0.7% | $96.72M-41.8% | ||
| $5.69M0.0% | $5.69M-34.0% | $5.69M-42.7% | $5.69M-62.7% | $5.69M-75.0% | ||
| 15.8B0.0% | 15.8B0.0% | 15.8B+315,999,900% | 15.8B0.0% | 15.8B0.0% | ||
| -$6.28B-4.9% | -$6.23B-5.1% | -$6.15B-5.4% | -$6.07B-5.9% | -$5.99B-5.6% | ||
| $420.28M-31.4% | $443.15M-31.6% | $508.59M-29.0% | $559.78M-29.8% | $612.95M-26.4% | ||
| $990.05M-19.6% | $1.03B-20.1% | $1.12B-18.7% | $1.19B-19.7% | $1.23B-24.3% |
FAQ
- What are Ginkgo Bioworks's total assets?
- Ginkgo Bioworks (DNA) holds $990.0M in total assets, down 19.6% year over year.
- How much debt does Ginkgo Bioworks have?
- Ginkgo Bioworks carries $404.1M in total debt against $420.3M of shareholders' equity, a debt-to-equity ratio of 0.96.
- How much cash does Ginkgo Bioworks have?
- Ginkgo Bioworks holds $172.0M in cash and equivalents.
- Can Ginkgo Bioworks cover its short-term obligations?
- Its current ratio is 4.57 — current assets exceed current liabilities.
- Where does Ginkgo Bioworks's balance sheet data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
